Zhong Y, Yang J, Xu W W, Wang Y, Zheng C-C, Li B, He Q-Y
Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, College of Life Science and Technology, Jinan University, Guangzhou, China.
Department of Pathology, Medical College, Jinan University, Guangzhou, China.
Oncogene. 2017 Nov 2;36(44):6177-6189. doi: 10.1038/onc.2017.287. Epub 2017 Sep 4.
Cell cycle dysregulation leads to uncontrolled cell proliferation and tumorigenesis. Understanding the molecular mechanisms underlying cell cycle progression can provide clues leading to the identification of key proteins involved in cancer development. In this study, we performed proteomics analysis to identify novel regulators of the cell cycle. We found that potassium channel tetramerization domain containing 12 (KCTD12) was significantly upregulated in M phase compared with S phase. We also found that KCTD12 overexpression not only facilitated the G2/M transition and induced cancer cell proliferation, but also promoted the growth of subcutaneous tumors and Ki-67 proliferation index in mice. Regarding the mechanism underlying these phenomena, cyclin-dependent kinase 1 (CDK1) was identified as an interacting partner of KCTD12 by immunoprecipitation and mass spectrometry analysis, which showed that KCTD12 activated CDK1 and Aurora kinase A (Aurora A) and that the effects of KCTD12 on CDK1 phosphorylation and cell proliferation were abrogated by cell division cycle 25B (CDC25B) silencing. In addition, Aurora A phosphorylated KCTD12 at serine 243, thereby initiating a positive feedback loop necessary for KCTD12 to exert its cancer-promoting effects. Furthermore, we analyzed the expression levels of various genes and the correlations between the expression of these genes and survival using tumor tissue microarray and Gene Expression Omnibus (GEO) data sets. The data showed that KCTD12 expression was significantly upregulated in cervical and lung cancers. More importantly, high KCTD12 expression was associated with larger tumor sizes, higher pathological stages and poor patient survival. Collectively, our study demonstrate that KCTD12 binds to CDC25B and activates CDK1 and Aurora A to facilitate the G2/M transition and promote tumorigenesis and that Aurora A phosphorylates KCTD12 at serine 243 to trigger a positive feedback loop, thereby potentiating the effects of KCTD12. Thus, the KCTD12-CDC25B-CDK1-Aurora A axis has important implications for cancer diagnoses and prognoses.
细胞周期失调会导致细胞不受控制地增殖和肿瘤发生。了解细胞周期进程背后的分子机制可以为识别参与癌症发展的关键蛋白提供线索。在本研究中,我们进行了蛋白质组学分析以鉴定细胞周期的新型调节因子。我们发现,与S期相比,含钾通道四聚化结构域12(KCTD12)在M期显著上调。我们还发现,KCTD12的过表达不仅促进了G2/M期转换并诱导癌细胞增殖,还促进了小鼠皮下肿瘤的生长以及Ki-67增殖指数。关于这些现象背后的机制,通过免疫沉淀和质谱分析确定细胞周期蛋白依赖性激酶1(CDK1)是KCTD12的相互作用伙伴,这表明KCTD12激活了CDK1和极光激酶A(Aurora A),并且细胞分裂周期2蛋白5B(CDC25B)的沉默消除了KCTD12对CDK1磷酸化和细胞增殖的影响。此外,Aurora A在丝氨酸243处磷酸化KCTD12,从而启动KCTD12发挥其促癌作用所必需的正反馈回路。此外,我们使用肿瘤组织微阵列和基因表达综合数据库(GEO)数据集分析了各种基因的表达水平以及这些基因表达与生存之间的相关性。数据显示,KCTD12在宫颈癌和肺癌中表达显著上调。更重要的是,KCTD12高表达与更大的肿瘤大小、更高的病理分期和患者较差的生存率相关。总的来说,我们的研究表明,KCTD12与CDC25B结合并激活CDK1和Aurora A以促进G2/M期转换并促进肿瘤发生,并且Aurora A在丝氨酸243处磷酸化KCTD12以触发正反馈回路,从而增强KCTD12的作用。因此,KCTD12-CDC25B-CDK1-Aurora A轴对癌症诊断和预后具有重要意义。